Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
- Lawmakers Urge Chuikyo to Respect Public-Private Council Views
September 11, 2025
- MHLW Panel Urges Tighter Scrutiny of GLP-1 “Weight Loss” Ads
September 11, 2025
- JPMA Pushes for Mandatory Collection of Medical Data, JMA Fires Back
September 11, 2025
- Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Label Revisions Ordered for Antihypertensives, Adalimumab, I/O Meds, and More
September 10, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- MHLW Seeks to Raise Quality of Prefectural Generic GMP Inspections
September 8, 2025
- MHLW Panel Backs Draft ARI Prevention Guidelines, Due Out November
September 5, 2025
- Japan Kicks Off Debate on Medical Data Use Framework, Eyes 2027 Legislation
September 4, 2025
- MHLW Seeks Sponsor for Drug Loss Product Trifarotene
September 4, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Generics Surge in FY2024 on New Out-of-Pocket Rule for Long-listed Drugs
September 3, 2025
- Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
- Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
- METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…